Impax Laboratories Profile

Impax Laboratories Patent Grants

Controlled release formulations of levodopa and uses thereof

Patent Number 9533046 - January 3, 2017

The current invention provides a controlled release oral solid formulation of levodopa comprising levodopa, a decarboxylase inhibitor, and a…

Controlled release formulations of levodopa and uses thereof

Patent Number 9463246 - October 11, 2016

The current invention provides a controlled release oral solid formulation of levodopa comprising levodopa, a decarboxylase inhibitor, and a…

Controlled release formulations of levodopa and uses thereof

Patent Number 9089607 - July 28, 2015

The current invention provides a controlled release oral solid formulation of levodopa comprising levodopa, a decarboxylase inhibitor, and a…

Controlled release formulations of levodopa and uses thereof

Patent Number 9089608 - July 28, 2015

The current invention provides a controlled release oral solid formulation of levodopa comprising levodopa, a decarboxylase inhibitor, and a…

Controlled release formulations of levodopa and uses thereof

Patent Number 8557283 - October 15, 2013

The current invention provides a controlled release oral solid formulation of levodopa comprising levodopa, a decarboxylase inhibitor, and a…

Impax Laboratories Patent Applications

CONTROLLED RELEASE FORMULATIONS OF LEVODOPA AND USES THEREOF

Application Number 20120177731 - July 12, 2012

The current invention provides a controlled release oral solid formulation of levodopa comprising levodopa, a decarboxylase inhibitor, and a…

Oral disintegrating dosage forms

Application Number 20050147670 - July 7, 2005

The invention is directed to pharmaceutical dosage forms having immediate release via rapid oral disintegration, specifically, orally…

Impax Laboratories Federal District Court Decisions

Impax Laboratories, Inc. v. Turing Pharmaceuticals AG

New York Southern District Court - November 16, 2016

OPINION AND ORDER. For the foregoing reasons, Defendant's motion to dismiss with prejudice Plaintiff's unjust enrichment claim…

Fleming v. Impax Laboratories Inc. et al

California Northern District Court - November 15, 2016

ORDER by Judge Haywood S. Gilliam, Jr. Granting 6 Motion for Pro Hac Vice as to Lieberman, Jeremy. (ndrS, COURT STAFF) (Filed on…

Fleming v. Impax Laboratories Inc. et al

California Northern District Court - November 15, 2016

ORDER by Judge Haywood S. Gilliam, Jr. Granting 7 Motion for Pro Hac Vice as to Hood, J. (ndrS, COURT STAFF) (Filed on 11/15/2016)

ENDO PHARMACEUTICALS INC. v. IMPAX LABORATORIES, INC.

New Jersey District Court - October 25, 2016

OPINION. Signed by Judge Jose L. Linares on 10/25/16. (DD, )

FEDERAL TRADE COMMISSION v. ENDO PHARMACEUTICALS INC. et al

Pennsylvania Eastern District Court - October 20, 2016

MEMORANDUM AND ORDER THAT DEFENDANTS' MOTIONS TO SEVER (DOC.NOS.57,58) ARE GRANTED. IT IS FURTHER ORDERED THAT THIS ACTION SHALL BE…

Impax Laboratories State Court Decisions

Impax Laboratories, Inc. v. Turing Pharmaceuticals AG

New York New York Southern District Court - November 16, 2016

OPINION AND ORDER. For the foregoing reasons, Defendant's motion to dismiss with prejudice Plaintiff's unjust enrichment claim…

ENDO PHARMACEUTICALS INC. v. IMPAX LABORATORIES, INC.

New Jersey New Jersey District Court - October 25, 2016

OPINION. Signed by Judge Jose L. Linares on 10/25/16. (DD, )

IMPAX LABORATORIES, INC. v. ACTAVIS LABORATORIES FL, INC. et al

New Jersey New Jersey District Court - May 27, 2016

OPINION/ORDER granting in part and denying in part 43 Motion to Stay; that Impax shall provide the Court with status updates regarding the ex…

linus Aruliah v. Impax Laboratories, Inc. et al

California California Northern District Court - December 21, 2015

ORDER APPROVING SETTLEMENT AND FINAL JUDGMENT signed by Hon. James Donato on December 21, 2015. (jdlc1S, COURT STAFF) (Filed on 12/21/2015)

Impax Laboratories Inc. et al v. Lannett Holdings Inc. et al

Delaware Delaware District Court - December 1, 2015

MEMORANDUM OPINION providing claim construction for disputed terms in U.S. Patent Nos. 6,750,237 and 7,220,767. Within five days the parties…